

MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary
November 2, 2016

In Attendance:

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	Ward Brown, M.D.	No
3	Catherine Decker, PharmD	Yes
4	Ronald Diamond, M.D.	No
5	John J. W. Fangman, M.D.	Yes
6	Lawrence Fleming, M.D.	No
7	Kevin Izard, M.D.	Yes - arrived @ 11:15 am
8	Steve Maike, RPh	Yes
9	Robert Rohloff, M.D.	Yes - Left @ 2:00 pm (prior to voting session)
10	William E. Raduege, M.D.	Yes
11	Pat Towers	Yes - arrived @ 9:30 am
12	Alicia Walker, PharmD	Yes - arrived @ 9:40 am
13	Michael Witkovsky, M.D.	Yes - arrived @ 9:40 am

November 2016 THERAPEUTIC DRUG CLASSES

ALZHEIMER'S AGENTS
ANTICONVULSANTS
ANTIDEPRESSANTS, OTHER
ANTIDEPRESSANTS, SSRIs
ANTIHISTAMINES, MINIMALLY SEDATING
ANTIHYPERTENSIVES, SYMPATHOLYTIC
ANTIHYPURICEMICS, ORAL
ANTIPARKINSON'S AGENTS
ANTIPSORIATICS, ORAL
ANTIPSORIATICS, TOPICAL
ANTIPSYCHOTICS (ORAL AND INJECTABLE)
ANXIOLYTICS
BILE SALTS
BRONCHODILATORS, BETA AGONIST
COPD AGENTS
COUGH AND COLD/NARCOTICS
CYTOKINE AND CAM ANTAGONISTS
EPINEPHRINE, SELF-INJECTED
ERYTHROPOIESIS STIMULATING PROTEINS
GLUCOCORTICOIDS, INHALED
GLUCOCORTICOIDS, ORAL
HEPATITIS C
HISTAMINE II RECEPTOR BLOCKERS
IMMUNOMODULATORS FOR ATOPIC DERMATITIS
IMMUNOMODULATORS, TOPICAL
INTRANASAL RHINITIS AGENTS
LEUKOTRIENE MODIFIERS
METHOTREXATE
NEUROPATHIC PAIN (ANALGESICS/ANESTHETICS TOPICAL AND FIBROMYALGIA)
NSAIDS
OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS
OPHTHALMIC ANTIBIOTICS
OPHTHALMIC ANTI-INFLAMMATORIES
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
OPHTHALMICS, GLAUCOMA AGENTS
OTIC ANTIBIOTICS
OTIC ANTI-INFECTIVES
SEDATIVE HYPNOTICS
STEROIDS, TOPICAL-HIGH POTENCY
STEROIDS, TOPICAL-LOW POTENCY
STEROIDS, TOPICAL-MEDIUM POTENCY
STEROIDS, TOPICAL-VERY HIGH POTENCY
STIMULANTS AND RELATED AGENTS

Recommendations Summary:

The following drug classes had no recommended changes since the November 11, 2015 Wisconsin Medicaid Pharmacy PA Advisory Committee (PAC) meeting and were approved by the Prior Authorization Committee (PAC) in a block vote. The PAC had no additional discussion regarding these drug classes.

Drug Classes included in the Committee block vote:

- ANTIDEPRESSANTS, SSRIs
- ANTIHISTAMINES, MINIMALLY SEDATING
- ANTIHYPERTENSIVES, SYMPATHOLYTIC
- ANTIHYPERURICEMICS, ORAL
- ANTIPARKINSON'S AGENTS
- ANTIPSORIATICS, ORAL
- ANXIOLYTICS
- BILE SALTS
- COUGH AND COLD/NARCOTICS
- ERYTHROPOIESIS STIMULATING PROTEINS
- GLUCOCORTICOIDS, ORAL
- HISTAMINE II RECEPTOR BLOCKERS
- IMMUNOMODULATORS FOR ATOPIC DERMATITIS
- IMMUNOMODULATORS, TOPICAL
- LEUKOTRIENE MODIFIERS
- METHOTREXATE
- NEUROPATHIC PAIN (ANALGESICS/ANESTHETICS TOPICAL AND FIBROMYALGIA)
- OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS
- OPHTHALMIC ANTIBIOTICS
- OPHTHALMICS, GLAUCOMA AGENTS
- OTIC ANTI-INFECTIVES AND ANESTHETICS
- STEROIDS, TOPICAL-LOW POTENCY

Drug Class removed from the Committee block vote based on discussion:

- Antidepressants, Other

- William Raduege made a motion to accept staff recommendations as presented
 - Second - Pat Towers
 - All members were in favor of the motion
 - Motion passes

ALZHEIMER'S AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MEMANTINE TABLET DOSE PACK (AG) (ORAL)	0.2%	ON	Yes-Gen			
DONEPEZIL TABLET (ORAL)	58.8%	ON	Yes-Gen			
MEMANTINE TABLET (AG) (ORAL)	2.0%	ON	Yes-Gen			
MEMANTINE TABLET (ORAL)	26.8%	ON	Yes-Gen			
DONEPEZIL ODT (ORAL)	0.4%	ON	Yes-Gen			
GALANTAMINE ER (ORAL)	0.5%	OFF	No-Gen			
RIVASTIGMINE CAPSULES (ORAL)	2.2%	ON	Yes-Gen			
EXELON (TRANSDERM.)	3.7%	ON	Yes			
GALANTAMINE TABLET (ORAL)	0.6%	OFF	No-Gen			
NAMENDA XR (ORAL)	4.2%	OFF	No			
NAMENDA SOLUTION (ORAL)	0.0%	ON	Yes			
NAMZARIC (ORAL)	0.2%	OFF	No			
DONEPEZIL 23 MG (ORAL)	0.3%	OFF	No-Gen			
NAMENDA TABLET DOSE PACK (ORAL)	0.0%	OFF	No			
GALANTAMINE SOLUTION (ORAL)	0.0%	OFF	No-Gen			
RIVASTIGMINE (AG) (TRANSDERM.)	0.1%	OFF	No-Gen			
RIVASTIGMINE (TRANSDERM.)	0.0%	OFF	No-Gen			
MEMANTINE SOLUTION (ORAL)	0.0%	NR	No-Gen			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented
 - Second - Alicia Walker
 - All members were in favor of the motion
 - Motion passes

ANTICONVULSANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLONAZEPAM (ORAL)	24.6%	ON	Yes-Gen			
PHENOBARBITAL TABLET (ORAL)	0.8%	ON	Yes-Gen			
CLONAZEPAM ODT (ORAL)	0.2%	OFF	No-Gen			
PHENOBARBITAL ELIXIR (ORAL)	0.4%	ON	Yes-Gen			
DIASTAT (RECTAL)	0.0%	ON	Yes			
DIASTAT ACUDIAL (RECTAL)	0.4%	ON	Yes			
DIAZEPAM DEVICE (RECTAL)	0.0%	OFF	No-Gen			
DIAZEPAM (RECTAL)	0.0%	OFF	No-Gen			
OXCARBAZEPINE TABLETS (ORAL)	3.0%	ON	Yes-Gen			
TEGRETOL TABLET (ORAL)	1.5%	ON	Yes			
TEGRETOL SUSPENSION (ORAL)	0.1%	ON	Yes			
EQUETRO (ORAL)	0.0%	OFF	No			
CARBAMAZEPINE CHEWABLE TABLET (ORAL)	0.6%	ON	Yes-Gen			
CARBAMAZEPINE TABLET (ORAL)	0.3%	OFF	No-Gen			
TEGRETOL XR (ORAL)	0.7%	ON	Yes			
CARBAMAZEPINE ER (GENERIC CARBATROL) (ORAL)	0.9%	ON	Yes-Gen			
CARBAMAZEPINE SUSPENSION (ORAL)	0.0%	OFF	No-Gen			
CARBATROL (ORAL)	0.3%	ON	Yes			
CARBAMAZEPINE XR (ORAL)	0.0%	OFF	No-Gen			
OXCARBAZEPINE SUSPENSION (ORAL)	0.5%	ON	Yes-Gen			
TRILEPTAL SUSPENSION (ORAL)	0.1%	OFF	No			
OXTELLAR XR (ORAL)	0.0%	OFF	No			
APTIOM (ORAL)	0.1%	OFF	No			
PRIMIDONE (ORAL)	1.0%	ON	Yes-Gen			
DIVALPROEX TABLET (ORAL)	4.6%	ON	Yes-Gen			
CELONTIN (ORAL)	0.0%	ON	Yes			
VALPROIC ACID (ORAL)	0.2%	ON	Yes-Gen			
VALPROATE SYRUP (ORAL)	0.9%	ON	Yes-Gen			
PHENYTOIN SUSPENSION (ORAL)	0.1%	ON	Yes-Gen			
PHENYTOIN CHEWABLE TABLET (ORAL)	0.1%	ON	Yes-Gen			
DIVALPROEX SPRINKLE (AG) (ORAL)	0.0%	ON	Yes-Gen			
PHENYTOIN CAPSULE (ORAL)	1.1%	ON	Yes-Gen			
PEGANONE (ORAL)	0.0%	ON	Yes			
PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (ORAL)	0.1%	ON	Yes-Gen			
ETHOSUXIMIDE CAPSULE (AG) (ORAL)	0.0%	NR	Yes-Gen			
DILANTIN INFATAB (ORAL)	0.1%	ON	Yes-Gen			
PHENYTEK (ORAL)	0.0%	OFF	No-Gen			
DIVALPROEX ER (ORAL)	7.0%	ON	Yes-Gen			
DIVALPROEX SPRINKLE (ORAL)	0.9%	ON	Yes-Gen			
ETHOSUXIMIDE CAPSULE (ORAL)	0.2%	ON	Yes-Gen			
ETHOSUXIMIDE SYRUP (ORAL)	0.2%	ON	Yes-Gen			
FELBAMATE TABLET (ORAL)	0.2%	ON	Yes-Gen			
FELBAMATE SUSPENSION (ORAL)	0.2%	ON	Yes-Gen			
FELBATOL TABLET (ORAL)	0.1%	OFF	No			
FELBATOL SUSPENSION (ORAL)	0.1%	OFF	No			
TOPIRAMATE ER (QUDEXY) (AG) (ORAL)	0.0%	OFF	No-Gen			
TOPIRAMATE TABLETS (ORAL)	13.4%	ON	Yes-Gen			
LAMOTRIGINE TABLET (ORAL)	19.1%	ON	Yes-Gen			
LAMICTAL TABLET DOSE PACK (ORAL)	0.0%	ON	Yes			
ZONISAMIDE (ORAL)	1.8%	ON	Yes-Gen			
LEVETIRACETAM TABLETS (ORAL)	7.4%	ON	Yes-Gen			
LEVETIRACETAM SOLUTION (ORAL)	2.5%	ON	Yes-Gen			
GABTRIL (ORAL)	0.0%	ON	Yes			
LEVETIRACETAM ER (ORAL)	0.5%	ON	Yes-Gen			
LAMOTRIGINE TABLET DOSE PACK (ORAL)	0.0%	ON	Yes-Gen			
LAMICTAL ODT DOSE PACK (ORAL)	0.0%	OFF	No			
TOPIRAMATE SPRINKLE (ORAL)	0.3%	ON	Yes-Gen			
QUDEXY XR (ORAL)	0.0%	OFF	No			
POTIGA (ORAL)	0.0%	OFF	No			
TIAGABINE (ORAL)	0.0%	OFF	No-Gen			
LAMOTRIGINE ODT DOSE PACK (ORAL)	0.0%	NR	No-Gen			
VIMPAT TABLET (ORAL)	0.8%	OFF	No			
VIMPAT SOLUTION (ORAL)	0.1%	OFF	No			
FYCOMPA SUSPENSION (ORAL)	0.0%	NR	No			
TROKENDI XR (ORAL)	0.1%	OFF	No			
LAMICTAL ODT (ORAL)	0.0%	OFF	No			
ONFI TABLET (ORAL)	0.6%	OFF	No			
LAMICTAL XR (ORAL)	0.2%	OFF	No			
FYCOMPA TABLET (ORAL)	0.1%	OFF	No			
LAMOTRIGINE ODT (ORAL)	0.1%	OFF	No-Gen			
LAMICTAL XR DOSE PACK (ORAL)	0.0%	OFF	No			
LAMOTRIGINE XR (ORAL)	0.5%	OFF	No-Gen			
ONFI SUSPENSION (ORAL)	0.2%	OFF	No			
BRIVIACT TABLET (ORAL)	0.0%	NR	No			
BANZEL TABLET (ORAL)	0.2%	NR	No			
SPRITAM (ORAL)	0.0%	NR	No			
BANZEL SUSPENSION (ORAL)	0.1%	OFF	No			
BRIVIACT SOLUTION (ORAL)	0.0%	NR	No			
SABRIL POWDER PACK (ORAL)	0.0%	OFF	No			
SABRIL TABLET (ORAL)	0.0%	OFF	No			

- Discussion: Rachel Currans-Henry stated that during closed session, there was discussion about member access to anticonvulsants. To date, approximately 96% of anticonvulsant utilization is for preferred drugs. The Committee requested the Department review the prior authorization (PA) criteria and length of PA approvals for this class.
- Roseanne Barber made a motion to accept staff recommendations as presented
 - Second - Kevin Izard
 - All members were in favor of the motion
 - Motion passes

ANTIDEPRESSANTS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TRAZODONE (ORAL)	28.9%	ON	Yes-Gen			
VENLAFAXINE ER CAPSULES (ORAL)	21.5%	ON	Yes-Gen			
MIRTAZAPINE TABLET (ORAL)	12.2%	ON	Yes-Gen			
BUPROPION SR (ORAL)	9.4%	ON	Yes-Gen			
FORFIVO XL (ORAL)	0.0%	OFF	No			
VENLAFAXINE (ORAL)	2.3%	ON	Yes-Gen			
PRISTIQ (ORAL)	1.2%	OFF	No	Yes		
MARPLAN (ORAL)	0.0%	ON	Yes			
MIRTAZAPINE ODT (ORAL)	0.3%	ON	Yes-Gen			
BUPROPION (ORAL)	2.0%	ON	Yes-Gen			
BUPROPION XL (ORAL)	19.6%	ON	Yes-Gen			
PHENELZINE (ORAL)	0.0%	ON	Yes-Gen			
TRINTELLIX (ORAL)	0.6%	OFF	No			
KHEDEZLA (ORAL)	0.0%	OFF	No			
OLEPTRO ER (ORAL)	0.0%	OFF	No			
NEFAZODONE (ORAL)	0.1%	OFF	No-Gen			
DESVENLAFAXINE ER (KHEDEZLA) (AG) (ORAL)	0.0%	OFF	No-Gen			
VIIBRYD (ORAL)	1.2%	OFF	No			
VENLAFAXINE ER TABLETS (GENERIC) (ORAL)	0.0%	OFF	No-Gen			
FETZIMA (ORAL)	0.4%	OFF	No			
DESVENLAFAXINE ER (ORAL)	0.0%	OFF	No-Gen			
VENLAFAXINE ER TABLETS (SCHWARZ) (AG) (ORAL)	0.1%	OFF	No-Gen			
APLENZIN (ORAL)	0.0%	OFF	No			
VIIBRYD DOSE PACK (ORAL)	0.0%	OFF	No			
DESVENLAFAXINE FUMARATE ER (ORAL)	0.0%	OFF	No-Gen			
VENLAFAXINE ER TABLETS (UPSTATE) (AG) (ORAL)	0.0%	OFF	No-Gen			
TRANLYCYPROMINE SULFATE (ORAL)	0.0%	ON	Yes-Gen			
NARDIL (ORAL)	0.0%	ON	Yes			
EMSAM (TRANSDERMAL)	0.0%	OFF	No			

- Discussion:
 - Michael Witkovsky made a motion to prefer Pristiq (Oral) and accept all other staff recommendations
 - Second - Roseanne Barber
 - Discussion of motion to prefer Pristiq (Oral) and accept all other staff recommendations: There was discussion about the potential side effects of

venlafaxine medications, and Michael Witkovsky stated that Pristiq’s dosing is simpler and has fewer side effects compared to venlafaxine.

Michael Witkovsky recommended the state consider adding Trintellix and Emsam as preferred in the next Committee meeting.

- All members were in favor of the motion
- Motion passes

ANTIPSORIATICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VECTICAL (TOPICAL)	2.8%	ON	Yes			
SORILUX (TOPICAL)	0.0%	OFF	No			
TACLONEX SCALP (TOPICAL)	7.9%	ON	Yes			
CALCIPOTRIENE SOLUTION (TOPICAL)	6.6%	ON	Yes-Gen			
CALCIPOTRIENE OINTMENT (TOPICAL)	20.9%	ON	Yes-Gen			
CALCITRIOL OINTMENT (TOPICAL)	0.0%	OFF	No-Gen			
CALCITRENE (TOPICAL)	1.8%	ON	Yes-Gen			
CALCIPOTRIENE CREAM (TOPICAL)	55.4%	ON	Yes-Gen			
ENSTILAR (TOPICAL)	1.3%	NR	No			
CALCIPOTRIENE/BETAMETHASONE OINTMENT (AG) (TOPICA	2.6%	OFF	No-Gen			
CALCIPOTRIENE/BETAMETHASONE OINTMENT (TOPICAL)	0.8%	OFF	No-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented
 - Second - John Fangman
 - All members were in favor of the motion
 - Motion Passes

ANTIPSYCHOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RISPERIDONE TABLET (ORAL)	19.3%	ON	Yes-Gen			
QUETIAPINE TABLETS (ORAL)	29.7%	ON	Yes-Gen			
OLANZAPINE TABLET (ORAL)	8.0%	ON	Yes-Gen			
ZIPRASIDONE CAPSULE (ORAL)	6.1%	ON	Yes-Gen			
OLANZAPINE ODT (ORAL)	0.3%	OFF	Yes-Gen			
CLOZAPINE (ORAL)	2.4%	ON	Yes-Gen			
FAZACLO (ORAL)	0.0%	OFF	No			
RISPERIDONE ODT (ORAL)	0.5%	ON	Yes-Gen			
SEROQUEL XR (ORAL)	1.4%	OFF	No			
LATUDA (ORAL)	5.9%	ON	Yes			
SAPHRIS (SUBLINGUAL)	0.6%	OFF	No			
ARIPIPRAZOLE TABLET (ORAL)	12.2%	ON	Yes-Gen			
FANAPT TABLET (ORAL)	0.2%	OFF	No			
CLOZAPINE ODT (AG) (ORAL)	0.1%	OFF	No-Gen			
CLOZAPINE ODT (ORAL)	0.0%	OFF	No-Gen			
INVEGA (ORAL)	1.2%	OFF	No			
RISPERIDONE SOLUTION (ORAL)	0.6%	ON	Yes-Gen			
VERSACLOZ (ORAL)	0.0%	OFF	No			
REXULTI (ORAL)	0.4%	OFF	No			
PALIPERIDONE (AG) (ORAL)	0.0%	OFF	No-Gen			
VRAYLAR (ORAL)	0.2%	NR	No			
PALIPERIDONE (ORAL)	0.0%	NR	No-Gen			
ARIPIPRAZOLE ODT (ORAL)	0.0%	NR	Yes-Gen			
ARIPIPRAZOLE SOLUTION (ORAL)	0.0%	ON	Yes-Gen			
NUPLAZID (ORAL)	0.0%	NR	No			
SYMBYAX (ORAL)	0.0%	OFF	No			
OLANZAPINE/FLUOXETINE (ORAL)	0.0%	OFF	No-Gen			
HALOPERIDOL DECANOATE (INJECTION)	1.0%	ON	Yes-Gen			
FLUPHENAZINE DECANOATE (INJECTION)	0.4%	ON	Yes-Gen			
HALDOL DECANOATE (INTRAMUSC)	0.0%	ON	Yes			
RISPERDAL CONSTA (INTRAMUSC.)	1.1%	ON	Yes			
ZYPREXA RELPREVV (INTRAMUSC)	0.0%	ON	Yes			
INVEGA SUSTENNA (INTRAMUSC)	1.5%	ON	Yes			
ABILIFY MAINTENA (INTRAMUSC.)	0.6%	ON	Yes			
ARISTADA (INTRAMUSC)	0.1%	NR	No			
INVEGA TRINZA (INTRAMUSC)	0.1%	ON	Yes			
HALOPERIDOL LACTATE CONC (ORAL)	0.0%	ON	Yes-Gen			
ORAP (ORAL)	0.1%	ON	Yes			
FLUPHENAZINE ELIXIR/SOLN (ORAL)	0.0%	ON	Yes-Gen			
HALOPERIDOL (ORAL)	3.1%	ON	Yes-Gen			
LOXAPINE (ORAL)	0.4%	ON	Yes-Gen			
THIORIDAZINE (ORAL)	0.1%	OFF	No-Gen			
FLUPHENAZINE TABLET (ORAL)	0.8%	ON	Yes-Gen			
TRIFLUOPERAZINE (ORAL)	0.2%	ON	Yes-Gen			
THIOTHIXENE (ORAL)	0.3%	ON	Yes-Gen			
PERPHENAZINE (ORAL)	0.3%	ON	Yes-Gen			
AMITRIPTYLINE / PERPHENAZINE (ORAL)	0.0%	ON	Yes-Gen			
ADASUVE (INHALATION)	0.0%	OFF	No			
PIMOZIDE (ORAL)	0.0%	NR	No-Gen			
MOLINDONE (ORAL)	0.0%	OFF	No-Gen			
CHLORPROMAZINE (ORAL)	0.5%	ON	Yes-Gen			

- Discussion: Michael Witkovsky stated the Department should consider having all injectable antipsychotics available as preferred, indicating compliance is easier and they are all long-acting. Additionally, Michael Witkovsky noted that Invega Trinza is preferred, but oral Invega is non-preferred, recommending that in some cases oral Invega should be an option before trying the injectable. Michael Witkovsky suggested the Committee revisit this issue at the next Committee meeting.

- William Raduege made a motion to accept staff recommendations as presented
 - Second - John Fangman
 - All members were in favor of the motion
 - Motion Passes

BRONCHODILATORS, BETA AGONIST						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SEREVENT (INHALATION)	0.2%	ON	Yes			
ARCAPTA NEOHALER (INHALATION)	0.0%	OFF	No			
STRIVERDI RESPIMAT (INHALATION)	0.0%	OFF	No			
ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)	11.2%	ON	Yes-Gen			
ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)	0.0%	ON	Yes-Gen			
ALBUTEROL NEB SOLN 100 MG/20 ML (INHALATION)	0.2%	ON	Yes-Gen			
ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)	0.5%	OFF	Yes-Gen			
XOPENEX NEB SOLN CONC (INHALATION)	0.0%	OFF	No			
LEVALBUTEROL NEB SOLN (INHALATION)	0.2%	OFF	No-Gen			
LEVALBUTEROL NEB SOLN CONC (INHALATION)	0.0%	OFF	No-Gen			
XOPENEX NEB SOLN (INHALATION)	0.0%	OFF	No-Gen			
METAPROTERENOL SYRUP (ORAL)	0.0%	OFF	No-Gen			
ALBUTEROL SYRUP (ORAL)	0.1%	ON	Yes-Gen			
METAPROTERENOL TABLET (ORAL)	0.0%	OFF	No-Gen			
TERBUTALINE (ORAL)	0.0%	ON	Yes-Gen			
ALBUTEROL ER (ORAL)	0.0%	ON	Yes-Gen			
ALBUTEROL TABLET (ORAL)	0.0%	ON	Yes-Gen			
PERFORMIST (INHALATION)	0.1%	OFF	No			
BROVANA (INHALATION)	0.1%	OFF	No			
PROVENTIL HFA (INHALATION)	14.2%	ON	Yes			
PROAIR HFA (INHALATION)	72.1%	ON	Yes			
XOPENEX HFA (INHALATION)	0.4%	OFF	No			
VENTOLIN HFA (INHALATION)	0.6%	OFF	No			
PROAIR RESPICLICK (INHALATION)	0.0%	OFF	No			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented
 - Second - Catherine Decker
 - All members were in favor of the motion
 - Motion Passes

COPD AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SPIRIVA (INHALATION)	49.0%	ON	Yes			
IPRATROPIUM NEBULIZER (INHALATION)	2.0%	ON	Yes-Gen			
IPRATROPIUM / ALBUTEROL (INHALATION)	16.9%	ON	Yes-Gen			
ATROVENT HFA (INHALATION)	3.8%	ON	Yes			
INCRUSE ELLIPTA (INHALATION)	0.4%	OFF	No			
ANORO ELLIPTA (INHALATION)	0.7%	OFF	No			
TUDORZA PRESSAIR (INHALATION)	0.7%	OFF	No			
COMBIVENT RESPIMAT (INHALATION)	22.8%	ON	Yes			
STIOLTO RESPIMAT (INHALATION)	0.3%	OFF	No			
SPIRIVA RESPIMAT (INHALATION)	1.2%	OFF	No			
DALIRESP (ORAL)	2.1%	OFF	No			
SEEBRI NEOHALER (INHALATION)	0.0%	NR	No			
UTIBRON NEOHALER (INHALATION)	0.0%	NR	No			
BEVESPI AEROSPHERE (INHALATION)	0.0%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented
 - Second-John Fangman
 - All members were in favor of the motion
 - Motion Passes

CYTOKINE AND CAM ANTAGONISTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ENBREL KIT (INJECTION)	0.8%	ON	Yes			
OTEZLA (ORAL)	2.1%	OFF	Yes			
SIMPONI SYRINGE (INJECTION)	0.1%	OFF	No			
KINERET (INJECTION)	0.5%	OFF	No			
ENBREL SYRINGE (INJECTION)	5.5%	ON	Yes			
ENBREL PEN (INJECTION)	19.6%	ON	Yes			
CIMZIA SYRINGE KIT (INJECTION)	3.1%	OFF	No			
HUMIRA KIT (INJECTION)	8.2%	ON	Yes			
COSENTYX PEN INJECTER (SUBCUTANE.)	0.6%	OFF	No			
COSENTYX SYRINGE (SUBCUTANE.)	0.0%	OFF	No			
HUMIRA PEN KIT (INJECTION)	53.2%	ON	Yes			
SIMPONI PEN INJECTER (INJECTION)	0.8%	OFF	No			
XELJANZ (ORAL)	1.1%	OFF	No			
XELJANZ XR (ORAL)	0.3%	NR	No			
ORENCIA SYRINGE (SUBCUTANE.)	2.1%	OFF	No			
CIMZIA KIT (INJECTION)	0.2%	OFF	No			
ACTEMRA SYRINGE (SUBCUTANE.)	0.8%	OFF	No			
ORENCIA CLICKJECT (SUBCUTANE.)	0.0%	NR	No			
TALTZ AUTOINJECTOR (SUBCUTANE.)	0.0%	NR	No			
TALTZ SYRINGE (SUBCUTANE.)	0.0%	NR	No			
STELARA SYRINGE (INJECTION)	1.0%	OFF	No			

- Discussion: Rachel Currans-Henry stated that the clinical prior authorization process for rheumatoid arthritis was discussed during closed session, including that clinical prior authorization is required for the use of all drugs in this class. In addition, currently Enbrel and Humira are required to be the first drug used for all disease states for which they are approved. The Department is reviewing clinical criteria and forms to determine if any changes need to be made.

John Fangman indicated Dr. Dan Malone, a speaker in the morning, made an important point about the differences between member's intolerance compared to lack of therapeutic response to medications in this class. Specifically, in cases where there is a lack of a therapeutic response to a tumor necrosis factor (TNF) inhibitor, there should not be a requirement to step through a second TNF inhibitor before a medication in the class with a different mechanism of action is allowed. John Fangman additionally stated side-effects from a TNF inhibitor should not prevent the use of a second TNF inhibitor.

- John Fangman made a motion to accept staff recommendations as presented
 - Second - Steve Maike
 - All members were in favor of the motion
 - Motion Passes

EPINEPHRINE, SELF-INJECTED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPINEPHRINE 0.15 MG (ADRENACLICK) (AG) (INJECTION)	0.0%	OFF	Yes			
EPINEPHRINE 0.3 MG (ADRENACLICK) (AG) (INJECTION)	0.0%	OFF	Yes			
EPIPEN (INTRAMUSC)	80.0%	ON	Yes-Gen			
EPIPEN JR (INTRAMUSC)	20.0%	ON	Yes-Gen			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented
 - Second - William Raduege
 - All members were in favor of the motion
 - Motion Passes

ERYTHROPOIESIS STIMULATING PROTEINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPOGEN (INJECTION)	0.0%	OFF	No			
ARANESP VIAL (INJECTION)	7.1%	ON	Yes			
ARANESP DISP SYRIN (INJECTION)	51.8%	ON	Yes			
PROCRIT (INJECTION)	41.1%	ON	Yes			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented
 - Second - Pat Towers
 - All members were in favor of the motion
 - Motion Passes

GLUCOCORTICOIDS, INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SYMBICORT (INHALATION)	22.7%	ON	Yes			
ADVAIR DISKUS (INHALATION)	36.7%	ON	Yes			
DULERA (INHALATION)	5.8%	ON	Yes			
ADVAIR HFA (INHALATION)	0.7%	OFF	No			
BREO ELLIPTA (INHALATION)	0.6%	OFF	No			
ASMANEX (INHALATION)	2.4%	ON	Yes			
QVAR (INHALATION)	22.3%	ON	Yes			
ALVESCO (INHALATION)	0.1%	OFF	No			
FLOVENT HFA (INHALATION)	1.6%	OFF	No			
PULMICORT FLEXHALER (INHALATION)	2.6%	ON	Yes			
FLOVENT DISKUS (INHALATION)	0.1%	OFF	No			
ARNUIITY ELLIPTA (INHALATION)	0.0%	OFF	No			
ASMANEX HFA (INHALATION)	0.0%	OFF	No			
AEROSPAN (INHALATION)	0.1%	ON	No			
PULMICORT 0.25, 0.5 MG RESPULES (INHALATION)	3.3%	ON	Yes			
BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)	0.3%	OFF	No-Gen			
PULMICORT 1 MG RESPULES (INHALATION)	0.5%	ON	Yes			
BUDESONIDE 1 MG RESPULES (INHALATION)	0.0%	OFF	No-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented
 - Second - Kevin Izard
 - All members were in favor of the motion
 - Motion Passes

HEPATITIS C TREATMENT COURSE						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZEPATIER (ORAL)	1.1%	ON	Yes			
TECHNIVIE (ORAL)	0.0%	ON	Yes			
VIEKIRA PAK (ORAL)	59.1%	ON	Yes			
HARVONI (ORAL) (12 WEEKS)	15.9%	OFF	No			
DAKLINZA (ORAL)	9.1%	ON	No			
OLYSIO (ORAL)	0.0%	OFF	No			
SOVALDI (ORAL)	14.8%	OFF	No			
EPCLUSA (ORAL)	0.0%	OFF	Yes			

- Discussion: Rachel Currans-Henry stated the Department recognizes the Committee has asked for the Hepatitis C class to be reviewed frequently, and though the class was reviewed and availability of the medications in this class broadened based on the Committee meeting in May 2016 (and was next scheduled to be reviewed in May 2017), the class is being reviewed in this Committee meeting given Provider Synergies received new bids for drugs in this class and a new medication is available.

John Fangman stated the Department should be commended for their work with this class, meeting the goals to improve member access and updating the Committee on these efforts.

Kevin Izard inquired about which members may be treated with medications in this class. Rachel Currans-Henry responded that members with a Metavir score of F2 or higher (F2, F3, and F4) may currently be treated. In addition, criteria related to drug and/or alcohol use are utilized. Lynn Radmer indicated that the Department now allows a FibroScan to identify members with a Metavir Score of F2, where a liver biopsy was required in the past.

- John Fangman made a motion to accept staff recommendations as presented
 - Second-Kevin Izard
 - All members were in favor of the motion
 - Motion Passes

INTRANASAL RHINITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PATANASE (NASAL)	2.0%	ON	Yes			
AZELASTINE (ASTELIN) (NASAL)	0.2%	OFF	No-Gen			
AZELASTINE (ASTEPRO) (AG) (NASAL)	0.0%	OFF	No-Gen			
AZELASTINE (ASTEPRO) (NASAL)	0.1%	OFF	No-Gen			
ASTEPRO (NASAL)	0.1%	OFF	No			
OLOPATADINE (NASAL)	0.0%	OFF	No-Gen			
OLOPATADINE (AG) (NASAL)	0.0%	OFF	No-Gen			
IPRATROPIUM (NASAL)	1.9%	ON	Yes-Gen			
FLUTICASONE (NASAL)	84.6%	ON	Yes-Gen			
ZETONNA (NASAL)	0.1%	OFF	No			
OMNARIS (NASAL)	0.1%	OFF	No			
QNASL 80 (NASAL)	0.2%	OFF	No			
VERAMYST (NASAL)	0.2%	OFF	No			
BECONASE AQ (NASAL)	0.3%	ON	Yes			
QNASL 40 (NASAL)	0.0%	OFF	No			
DYMISTA (NASAL)	0.2%	OFF	No			
FLUNISOLIDE (NASAL)	0.0%	OFF	No-Gen			
BUDESONIDE (AG) (NASAL)	0.0%	OFF	No-Gen			
NASONEX (NASAL)	9.8%	ON	No			
BUDESONIDE (NASAL)	0.0%	OFF	No-Gen			
MOMETASONE (AG) (NASAL)	0.0%	OFF	No-Gen			
MOMETASONE (NASAL)	0.0%	OFF	No-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented
 - Second - Michael Witkovsky
 - All members were in favor of the motion
 - Motion Passes

NSAIDS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SPRIX (NASAL)	0.0%	OFF	No			
MELOXICAM TABLET (ORAL)	16.2%	ON	Yes-Gen			
MOBIC SUSPENSION (ORAL)	0.0%	OFF	No			
IBUPROFEN TABLET OTC (ORAL)	1.5%	ON	Yes-Gen			
ADVIL MIGRAINE CAPSULE OTC (ORAL)	0.0%	ON	Yes			
ADVIL OTC (ORAL)	0.0%	ON	Yes			
ADVIL TAB CHEW OTC (ORAL)	0.0%	ON	Yes			
NAPROXEN SODIUM OTC (ORAL)	0.5%	ON	Yes-Gen			
VOLTAREN (TOPICAL)	6.4%	ON	Yes			
NAPROXEN TABLET (ORAL)	15.0%	ON	Yes-Gen			
IBUPROFEN TABLET (ORAL)	32.3%	ON	Yes-Gen			
IBUPROFEN CAPSULE OTC (ORAL)	0.0%	ON	Yes-Gen			
INDOMETHACIN CAPSULE (ORAL)	1.9%	ON	Yes-Gen			
IBUPROFEN TAB CHEW OTC (ORAL)	0.0%	ON	Yes-Gen			
IBUPROFEN DROPS SUSPENSION OTC (ORAL)	0.0%	ON	Yes-Gen			
INDOCIN SUSPENSION (ORAL)	0.0%	OFF	No			
IBUPROFEN SUSPENSION OTC (ORAL)	1.3%	ON	Yes-Gen			
DICLOFENAC SR (ORAL)	0.2%	ON	Yes-Gen			
IBUPROFEN SUSPENSION (ORAL)	8.2%	ON	Yes-Gen			
NAPROXEN EC (ORAL)	0.4%	ON	Yes-Gen			
DICLOFENAC SODIUM (ORAL)	8.1%	ON	Yes-Gen			
KETOROLAC (ORAL)	1.8%	ON	Yes-Gen			
SULINDAC (ORAL)	0.4%	ON	Yes-Gen			
FLURBIPROFEN (ORAL)	0.0%	ON	Yes-Gen			
NABUMETONE (ORAL)	1.5%	ON	Yes-Gen			
CELECOXIB (AG) (ORAL)	0.3%	OFF	No-Gen			
KETOPROFEN (ORAL)	0.1%	ON	Yes-Gen			
ETODOLAC (ORAL)	0.1%	OFF	No-Gen			
MELOXICAM SUSPENSION (ORAL)	0.0%	OFF	No-Gen			
DICLOFENAC POTASSIUM (ORAL)	1.0%	ON	Yes-Gen			
CELECOXIB (ORAL)	1.4%	OFF	No-Gen			
NAPRELAN (ORAL)	0.0%	OFF	No			
ETODOLAC TAB SR (ORAL)	0.0%	OFF	No-Gen			
DICLOFENAC GEL (TOPICAL)	0.0%	NR	No-Gen			
FLECTOR (TOPICAL)	0.1%	OFF	No			
OXAPROZIN (ORAL)	0.0%	OFF	No-Gen			
ZORVOLEX (ORAL)	0.0%	OFF	No			
NAPROXEN SODIUM (ORAL)	1.0%	ON	No-Gen			
PIROXICAM (ORAL)	0.1%	OFF	No-Gen			
DIFLUNISAL (ORAL)	0.0%	OFF	No-Gen			
DICLOFENAC SODIUM/MISOPROSTOL (ORAL)	0.0%	OFF	No-Gen			
ZIPSOR (ORAL)	0.0%	OFF	No			
FENOPROFEN (AG) (ORAL)	0.0%	OFF	No-Gen			
FENOPROFEN (ORAL)	0.0%	OFF	No-Gen			
TIVORBEX (ORAL)	0.0%	OFF	No			
DUEXIS (ORAL)	0.0%	OFF	No			
VIMOVO (ORAL)	0.0%	OFF	No			
MECLOFENAMATE (ORAL)	0.0%	OFF	No-Gen			
INDOMETHACIN CAPSULE ER (ORAL)	0.0%	OFF	No-Gen			
DICLOFENAC SOLUTION (TOPICAL)	0.0%	OFF	No-Gen			
NAPROXEN SUSPENSION (ORAL)	0.1%	ON	Yes-Gen			
NALFON (ORAL)	0.0%	OFF	No			
MEFENAMIC ACID (ORAL)	0.0%	OFF	No-Gen			
TOLMETIN SODIUM CAPSULE (ORAL)	0.0%	OFF	No-Gen			
TOLMETIN SODIUM TABLET (ORAL)	0.0%	OFF	No-Gen			
INDOCIN (RECTAL)	0.0%	OFF	No-Gen			
VIVLODEX (ORAL)	0.0%	NR	No			
NAPROXEN CR (AG) (ORAL)	0.0%	OFF	No-Gen			
PENNSAID PUMP (TOPICAL)	0.0%	OFF	No			
NAPROXEN CR (ORAL)	0.0%	OFF	No-Gen			
KETOPROFEN ER (ORAL)	0.0%	OFF	No-Gen			
PONSTEL (ORAL)	0.0%	OFF	No			

- Discussion: Kevin Izard questioned why meloxicam is non-preferred, but diclofenac is preferred, even though they appear to be of similar cost. Rick Pope from Provider Synergies indicated the two drugs are not the same cost, and that meloxicam is indeed more expensive than diclofenac.

Alicia Walker indicated she thinks naproxen sodium should remain preferred. Catherine Decker stated that naproxen sodium OTC and naproxen tablet (oral) are still preferred.

- Kevin Izard made a motion to accept staff recommendations as presented
 - Second - Pat Towers
 - All members were in favor of the motion
 - Motion Passes

OPHTHALMICS, ANTI-INFLAMMATORIES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DICLOFENAC (OPHTHALMIC)	0.1%	OFF	No-Gen			
FLURBIPROFEN (OPHTHALMIC)	0.4%	ON	Yes-Gen			
KETOROLAC (OPHTHALMIC)	15.3%	ON	Yes-Gen			
ILEVRO (OPHTHALMIC)	0.0%	OFF	Yes			
ACUVAIL (OPHTHALMIC)	0.0%	OFF	No			
NEVANAC (OPHTHALMIC)	0.0%	OFF	No			
KETOROLAC LS (OPHTHALMIC)	7.7%	ON	Yes-Gen			
PROLENSA (OPHTHALMIC)	0.0%	OFF	No			
BROMFENAC (OPHTHALMIC)	0.1%	OFF	No-Gen			
ACULAR LS (OPHTHALMIC)	0.0%	OFF	No			
DUREZOL (OPHTHALMIC)	7.1%	ON	Yes			
LOTEMAX DROPS (OPHTHALMIC)	4.6%	ON	Yes			
FLUOROMETHOLONE (OPHTHALMIC)	7.5%	ON	Yes-Gen			
FLAREX (OPHTHALMIC)	0.0%	ON	Yes			
MAXIDEX (OPHTHALMIC)	0.1%	ON	Yes			
PRED MILD (OPHTHALMIC)	0.4%	ON	Yes			
FML FORTE (OPHTHALMIC)	0.2%	ON	Yes			
FML S.O.P. (OPHTHALMIC)	0.4%	ON	Yes			
VEXOL (OPHTHALMIC)	0.0%	OFF	No			
PREDNISOLONE SOD PHOSPHATE (OPHTHALMIC)	0.2%	ON	Yes-Gen			
DEXAMETHASONE (OPHTHALMIC)	2.6%	ON	Yes-Gen			
LOTEMAX OINTMENT (OPHTHALMIC)	0.1%	OFF	No			
PREDNISOLONE ACETATE (OPHTHALMIC)	52.9%	ON	Yes-Gen			
LOTEMAX GEL (OPHTHALMIC)	0.4%	OFF	No			
OMNIPRED (OPHTHALMIC)	0.0%	OFF	No-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented
 - Second - John Fangman
 - All members were in favor of the motion
 - Motion Passes

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BEPREVE (OPHTHALMIC)	0.1%	OFF	No			
LASTACAPT (OPHTHALMIC)	0.1%	OFF	No			
ALREX (OPHTHALMIC)	1.5%	ON	Yes			
ZADITOR OTC (OPHTHALMIC)	1.7%	ON	Yes-Gen			
KETOTIFEN OTC (OPHTHALMIC)	15.4%	ON	Yes-Gen			
PAZEO (OPHTHALMIC)	3.6%	ON	Yes			
PATADAY (OPHTHALMIC)	75.2%	ON	Yes			
EMADINE (OPHTHALMIC)	0.0%	OFF	No			
AZELASTINE (OPHTHALMIC)	0.1%	OFF	No-Gen			
EPINASTINE (OPHTHALMIC)	0.0%	OFF	No-Gen			
OLOPATADINE (PATANOL) (AG) (OPHTHALMIC)	0.0%	OFF	No-Gen			
OLOPATADINE (PATANOL) (OPHTHALMIC)	0.2%	NR	No-Gen			
CROMOLYN SODIUM (OPHTHALMIC)	2.0%	ON	Yes-Gen			
ALOMIDE (OPHTHALMIC)	0.0%	OFF	No			
ALOCRI (OPHTHALMIC)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented
 - Second - Michael Witkovsky
 - All members were in favor of the motion
 - Motion Passes

OTIC ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OFLOXACIN (OTIC)	0.0%	OFF	No-Gen			
CIPRO HC (OTIC)	37.6%	ON	Yes			
COLY-MYCIN S (OTIC)	0.3%	ON	Yes			
CORTISPORIN-TC (OTIC)	0.0%	OFF	No			
CIPRODEX (OTIC)	4.1%	OFF	No-Gen			
CIPROFLOXACIN (OTIC)	2.9%	ON	Yes-Gen			
NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)	55.1%	ON	Yes-Gen			
OTOVEL (OTIC)	0.0%	NR	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented
 - Second - William Raduege
 - All members were in favor of the motion
 - Motion Passes

SEDATIVE HYPNOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZOLPIDEM (ORAL)	73.2%	ON	Yes-Gen			
TEMAZEPAM (ORAL)	12.8%	ON	Yes-Gen			
ZALEPLON (ORAL)	2.7%	ON	Yes-Gen			
SILENOR (ORAL)	0.1%	OFF	No			
ESZOPICLONE (ORAL)	2.6%	OFF	No-Gen			
FLURAZEPAM (ORAL)	0.1%	OFF	No-Gen			
INTERMEZZO (SUBLINGUAL)	0.0%	OFF	No			
ESTAZOLAM (ORAL)	0.3%	ON	Yes-Gen			
ZOLPIMIST (ORAL)	0.0%	OFF	No			
TRIAZOLAM (ORAL)	1.1%	ON	Yes-Gen			
ZOLPIDEM ER (ORAL)	2.8%	OFF	No-Gen			
ROZEREM (ORAL)	3.0%	ON	Yes			
EDLUAR (SUBLINGUAL)	0.0%	OFF	No			
TEMAZEPAM 7.5 MG (ORAL)	0.0%	OFF	No-Gen			
TEMAZEPAM 22.5 MG (ORAL)	0.0%	OFF	No-Gen			
ZOLPIDEM (SUBLINGUAL)	0.0%	NR	No-Gen			
BELSOMRA (ORAL)	1.5%	OFF	No			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented
 - Second - William Raduege
 - All members were in favor of the motion
 - Motion Passes

STEROIDS, TOPICAL HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)	53.8%	ON	Yes-Gen			
TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)	33.7%	ON	Yes-Gen			
TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)	1.3%	ON	Yes-Gen			
BETAMETHASONE VALERATE OINTMENT (TOPICAL)	3.6%	ON	Yes-Gen			
BETAMETHASONE VALERATE CREAM (TOPICAL)	4.6%	ON	Yes-Gen			
BETAMETHASONE DIPROPIONATE LOTION (TOPICAL)	0.1%	OFF	No-Gen			
KENALOG AEROSOL (TOPICAL)	0.0%	OFF	No			
BETAMET DIPROP / PROP GLY CREAM (TOPICAL)	0.0%	OFF	No-Gen			
BETAMETHASONE VALERATE LOTION (TOPICAL)	1.6%	ON	Yes-Gen			
FLUOCINONIDE SOLUTION (TOPICAL)	0.2%	OFF	No-Gen			
FLUOCINONIDE EMOLLIENT (TOPICAL)	0.0%	OFF	No-Gen			
BETAMETHASONE DIPROPIONATE OINTMENT (TOPICAL)	0.1%	OFF	No-Gen			
BETAMETHASONE DIPROPIONATE CREAM (TOPICAL)	0.2%	OFF	No-Gen			
HALOG OINTMENT (TOPICAL)	0.0%	OFF	No			
FLUOCINONIDE OINTMENT (TOPICAL)	0.3%	OFF	No-Gen			
BETAMETHASONE DIPROPIONATE GEL (TOPICAL)	0.0%	OFF	No-Gen			
BETAMET DIPROP / PROP GLY LOTION (TOPICAL)	0.0%	OFF	No-Gen			
BETAMET DIPROP / PROP GLY OINTMENT (TOPICAL)	0.1%	OFF	No-Gen			
FLUOCINONIDE CREAM (TOPICAL)	0.3%	OFF	No-Gen			
HALOG CREAM (TOPICAL)	0.0%	OFF	No			
DIFLORASONE DIACETATE OINTMENT (TOPICAL)	0.0%	OFF	No-Gen			
DESOXIMETASONE CREAM (TOPICAL)	0.0%	OFF	No-Gen			
TOPICORT OINTMENT (TOPICAL)	0.0%	OFF	No			
FLUOCINONIDE GEL (TOPICAL)	0.0%	OFF	No-Gen			
TRIAMCINOLONE ACETONIDE AEROSOL (TOPICAL)	0.0%	OFF	No-Gen			
AMCINONIDE LOTION (TOPICAL)	0.0%	OFF	No-Gen			
AMCINONIDE CREAM (TOPICAL)	0.0%	OFF	No-Gen			
DESOXIMETASONE GEL (TOPICAL)	0.0%	OFF	No-Gen			
AMCINONIDE OINTMENT (TOPICAL)	0.0%	OFF	No-Gen			
TOPICORT SPRAY (TOPICAL)	0.0%	OFF	No			
DESOXIMETASONE OINTMENT (TOPICAL)	0.1%	OFF	No-Gen			
DIFLORASONE DIACETATE CREAM (TOPICAL)	0.0%	OFF	No-Gen			
SERNIVO SPRAY (TOPICAL)	0.0%	NR	No			
TRIANEX OINTMENT (TOPICAL)	0.0%	OFF	No-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented
 - Second-John Fangman
 - All members were in favor of the motion
 - Motion Passes

STERIODS, TOPICAL MEDIUM						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MOMETASONE FUROATE CREAM (TOPICAL)	20.1%	ON	Yes-Gen			
MOMETASONE FUROATE OINTMENT (TOPICAL)	23.9%	ON	Yes-Gen			
MOMETASONE FUROATE SOLUTION (TOPICAL)	5.5%	ON	Yes-Gen			
FLUTICASONE PROPIONATE CREAM (TOPICAL)	36.5%	ON	Yes-Gen			
FLUTICASONE PROPIONATE OINTMENT (TOPICAL)	12.2%	ON	Yes-Gen			
SYNALAR SOLUTION (TOPICAL)	0.0%	OFF	No			
HYDROCORTISONE BUTYRATE CREAM (AG) (TOPICAL)	0.1%	OFF	No-Gen			
SYNALAR CREAM (TOPICAL)	0.0%	OFF	No			
PREDNICARBATE CREAM (TOPICAL)	0.0%	OFF	No-Gen			
HYDROCORTISONE BUTYRATE/EMOLLIENT (AG) (TOPICAL)	0.0%	OFF	No-Gen			
LUXIQ (TOPICAL)	0.0%	OFF	No			
HYDROCORTISONE BUTYRATE CREAM (TOPICAL)	0.0%	OFF	No-Gen			
FLUOCINOLONE ACETONIDE CREAM (TOPICAL)	0.1%	OFF	No-Gen			
FLUOCINOLONE ACETONIDE OINTMENT (TOPICAL)	0.1%	OFF	No-Gen			
PREDNICARBATE OINTMENT (TOPICAL)	0.0%	OFF	No-Gen			
HYDROCORTISONE BUTYRATE OINTMENT (AG) (TOPICAL)	0.0%	OFF	No-Gen			
HYDROCORTISONE BUTYRATE OINTMENT (TOPICAL)	0.2%	OFF	No-Gen			
HYDROCORTISONE VALERATE CREAM (TOPICAL)	0.1%	OFF	No-Gen			
PANDEL (TOPICAL)	0.0%	OFF	No			
FLUOCINOLONE ACETONIDE SOLUTION (TOPICAL)	0.7%	OFF	No-Gen			
HYDROCORTISONE BUTYRATE SOLUTION (AG) (TOPICAL)	0.0%	OFF	No-Gen			
HYDROCORTISONE BUTYRATE SOLUTION (TOPICAL)	0.0%	OFF	No-Gen			
HYDROCORTISONE VALERATE OINTMENT (TOPICAL)	0.1%	OFF	No-Gen			
CLOCORTOLONE CREAM (AG) (TOPICAL)	0.1%	OFF	No-Gen			
CLODERM (TOPICAL)	0.0%	OFF	No			
FLURANDRENOLIDE CREAM (TOPICAL)	0.0%	NR	No-Gen			
HYDROCORTISONE BUTYRATE/EMOLLIENT (TOPICAL)	0.0%	OFF	No-Gen			
FLUTICASONE PROPIONATE LOTION (TOPICAL)	0.0%	OFF	No-Gen			
CORDRAN TAPE (TOPICAL)	0.2%	OFF	No			
BETAMETHASONE VALERATE FOAM (TOPICAL)	0.3%	OFF	No-Gen			
CUTIVATE LOTION (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented
 - Second – John Fangman
 - All members were in favor of the motion
 - Motion Passes

STERIODS, TOPICAL VERY HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOBEX SPRAY (TOPICAL)	0.2%	OFF	No			
CLOBEX LOTION (TOPICAL)	0.3%	ON	Yes			
CLOBEX SHAMPOO (TOPICAL)	1.5%	ON	Yes			
HALOBETASOL PROPIONATE OINTMENT (TOPICAL)	2.3%	ON	Yes-Gen			
CLOBETASOL PROPIONATE SOLUTION (TOPICAL)	20.6%	ON	Yes-Gen			
CLOBETASOL PROPIONATE CREAM (TOPICAL)	27.3%	ON	Yes-Gen			
OLUX-E (TOPICAL)	0.0%	OFF	No			
HALOBETASOL PROPIONATE CREAM (TOPICAL)	0.8%	ON	Yes-Gen			
CLOBETASOL EMOLLIENT (TOPICAL)	2.2%	ON	Yes-Gen			
CLOBETASOL PROPIONATE GEL (TOPICAL)	1.6%	ON	Yes-Gen			
CLOBETASOL PROPIONATE OINTMENT (TOPICAL)	42.7%	ON	Yes-Gen			
CLOBETASOL SHAMPOO (TOPICAL)	0.2%	OFF	No-Gen			
CLOBETASOL PROPIONATE SPRAY (TOPICAL)	0.0%	OFF	No-Gen			
CLOBETASOL PROPIONATE SPRAY (AG) (TOPICAL)	0.0%	OFF	No-Gen			
CLOBETASOL LOTION (TOPICAL)	0.1%	OFF	No-Gen			
CLOBETASOL PROPIONATE FOAM (TOPICAL)	0.2%	OFF	No-Gen			
ULTRAVATE LOTION (TOPICAL)	0.0%	NR	No			
APEXICON E (TOPICAL)	0.0%	OFF	No-Gen			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented
 - Second - William Raduege
 - All members were in favor of the motion
 - Motion Passes

STIMULANTS AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
KAPVAY (ORAL)	0.0%	OFF	Yes			
METADATE CD (ORAL)	2.2%	ON	Yes			
METHYLIN CHEWABLE TABLETS (ORAL)	0.0%	ON	Yes			
GUANFACINE ER (ORAL)	6.4%	ON	Yes-Gen			
DEXMETHYLPHENIDATE (AG) (ORAL)	0.2%	ON	Yes-Gen			
NUVIGIL (ORAL)	0.1%	OFF	No			
FOCALIN (ORAL)	0.0%	ON	Yes			
METHYLPHENIDATE (ORAL)	6.6%	ON	Yes-Gen			
DEXMETHYLPHENIDATE (ORAL)	0.9%	ON	Yes-Gen			
FOCALIN XR (ORAL)	4.5%	ON	Yes			
AMPHETAMINE SALT COMBO (ORAL)	17.6%	OFF	No-Gen			
VYVANSE (ORAL)	21.3%	ON	Yes			
ADZENYS XR ODT (ORAL)	0.0%	NR	No			
APTENSIO XR (ORAL)	0.0%	OFF	No			
QUILLIVANT XR (ORAL)	0.7%	ON	Yes			
RITALIN LA 10 MG CAPSULE (ORAL)	0.0%	OFF	No			
DAYTRANA (TRANSDERMAL)	0.2%	ON	Yes			
METHYLPHENIDATE ER (CONCERTA) (AG) (ORA	8.8%	ON	Yes-Gen			
AMPHETAMINE SALT COMBO ER (AG) (ORAL)	0.0%	OFF	No-Gen			
QUILLICHEW ER (ORAL)	0.0%	NR	Yes			
STRATTERA (ORAL)	3.7%	ON	Yes			
ADDERALL XR (ORAL)	20.7%	OFF	No			
ZENZEDI (ORAL)	0.0%	OFF	No-Gen			
AMPHETAMINE SALT COMBO ER (ORAL)	0.0%	OFF	No-Gen			
METHYLIN SOLUTION (ORAL)	0.0%	OFF	No			
DESOXYN (ORAL)	0.0%	OFF	No			
DEXTROAMPHETAMINE TABLET (ORAL)	0.6%	OFF	No-Gen			
DYANAVAL XR (ORAL)	0.0%	OFF	No			
METHYLPHENIDATE CD (AG) (ORAL)	0.0%	OFF	No-Gen			
METHYLPHENIDATE ER (GEN RITALIN LA) (ORAL	0.1%	OFF	Yes-Gen			
MODAFINIL (ORAL)	0.1%	OFF	No-Gen			
METHYLPHENIDATE ER (ORAL)	1.0%	ON	Yes-Gen			
EVEKEO (ORAL)	0.1%	OFF	No-Gen			
METHYLPHENIDATE SOLUTION (ORAL)	0.0%	OFF	Yes-Gen			
METHYLPHENIDATE ER (CONCERTA) (ORAL)	2.5%	ON	Yes-Gen			
CLONIDINE ER (ORAL)	0.4%	OFF	No-Gen			
DEXMETHYLPHENIDATE XR (ORAL)	0.0%	OFF	No-Gen			
METHYLPHENIDATE CD (ORAL)	0.0%	OFF	No-Gen			
DEXMETHYLPHENIDATE XR (AG) (ORAL)	0.0%	OFF	No-Gen			
DEXTROAMPHETAMINE CAPSULE ER (ORAL)	0.7%	OFF	No-Gen			
PROCENTRA (ORAL)	0.0%	OFF	No-Gen			
RITALIN LA (ORAL)	0.1%	OFF	No			
METHYLPHENIDATE SOLUTION (AG) (ORAL)	0.0%	OFF	No-Gen			
METHYLPHENIDATE CHEWABLE TABLETS (ORAL	0.0%	OFF	No-Gen			
ARMODAFINIL (AG) (ORAL)	0.0%	OFF	No-Gen			
ARMODAFINIL (ORAL)	0.0%	OFF	No-Gen			
METHAMPHETAMINE (ORAL)	0.0%	OFF	No-Gen			
DEXEDRINE SPANSULE (ORAL)	0.0%	OFF	No			
DEXTROAMPHETAMINE SOLUTION (ORAL)	0.0%	OFF	No-Gen			

- Discussion: Rachel Currans-Henry stated that there was discussion in closed session about previous decisions in this class, specifically that members are required to try Vyvanse and at least one other preferred stimulant prior to getting access to

amphetamines. The primary purpose of these policies is to limit member misuse of amphetamines.

Michael Witkovsky indicated that the absence of amphetamine products, Vyvanse being the exception, suggests Vyvanse is equal to other amphetamine products when this is not the case. Michael Witkovsky suggested the Department consider another long-acting amphetamine as preferred.

Kevin Izard questioned why a member who has attempted other amphetamines in the past would not be prescribed Vyvanse. Michael Witkovsky responded that amphetamines typically provide a better reward response for patients compared to Vyvanse.

Michael Witkovsky suggested the Department further research the pharmacological, clinical and financial differences between Vyvanse and other amphetamines.

- Pat Towers made a motion to accept staff recommendations as presented
 - Second-Michael Witkovsky
 - All members were in favor of the motion
 - Motion Passes